Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).

The source lists no authors.

Fertility and sterility1 Mar 1992Cited by 12 (Europe PMC)

PMID1531464PepBankPUB-01531464

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with endometriosis, the transaminase increase was significantly smaller with nafarelin than danazol (P less than 0.002).
In plain wordsIn patients with endometriosis, the liver enzyme increase was smaller with nafarelin than danazol.
Peptide
Nafarelin
Outcome
DecreaseTransaminase increase versus danazol
Study
n = 307
Comparator
Danazol
Outcome group
Liver fat and liver function · Liver
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
serum glutamic oxaloacetic transaminase increased in both groups (P less than 0.001 for both) but significantly more in danazol users (P less than 0.002)
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Report a problemFND-0153146406
02HumanRandomized controlled trialSafety outcome
In patients with endometriosis, more nafarelin recipients had hot flushes than danazol recipients (P less than 0.001).
In plain wordsIn patients with endometriosis, more nafarelin recipients had hot flushes than danazol recipients.
Peptide
Nafarelin
Outcome
IncreaseHot flushes
Study
n = 307
Comparator
Danazol
Outcome group
Adverse events · Whole body
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
and more nafarelin recipients had hot flushes (P less than 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Report a problemFND-0153146407
03HumanNon-randomized trialSafety outcome
In patients with endometriosis, serum glutamic oxaloacetic transaminase increased during nafarelin treatment, as with danazol (P less than 0.001).
In plain wordsIn patients with endometriosis, a liver enzyme increased during nafarelin treatment, as it did with danazol.
Peptide
Nafarelin
Outcome
IncreaseSerum glutamic oxaloacetic transaminase change
Study
n = 206
Comparator
Admission
Outcome group
Liver fat and liver function · Liver
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
serum glutamic oxaloacetic transaminase increased in both groups (P less than 0.001 for both) but significantly more in danazol users (P less than 0.002)
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Report a problemFND-0153146405
04HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, disease growth improved during nafarelin treatment, as it did with danazol (P less than 0.001).
In plain wordsIn patients with endometriosis, disease growth improved during nafarelin treatment, as it did with danazol.
Peptide
Nafarelin
Outcome
DecreaseEndometriosis growth during treatment
Study
n = 171
Comparator
Admission
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
In each group, endometriosis growth and symptoms significantly improved during treatment (P less than 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Summary · context
Nafarelin and danazol were equally effective in reducing endometriosis growth and symptoms during treatment and in preventing the return of symptoms during 12-month follow-up.
Report a problemFND-0153146401
05HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, symptoms improved during nafarelin treatment, as they did with danazol (P less than 0.001).
In plain wordsIn patients with endometriosis, symptoms improved during nafarelin treatment, as they did with danazol.
Peptide
Nafarelin
Outcome
DecreaseSymptoms during treatment
Study
n = 171
Comparator
Admission
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
In each group, endometriosis growth and symptoms significantly improved during treatment (P less than 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Summary · context
Nafarelin and danazol were equally effective in reducing endometriosis growth and symptoms during treatment and in preventing the return of symptoms during 12-month follow-up.
Report a problemFND-0153146402
06HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, symptoms returned after nafarelin cessation, as they did after danazol.
In plain wordsIn patients with endometriosis, symptoms returned after nafarelin cessation, as they did after danazol.
Peptide
Nafarelin
Outcome
IncreaseSymptom recurrence after treatment
Study
n = 171
Comparator
End of treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After treatment, symptoms returned in each group, but severity was less than at admission at all time points (P less than or equal to 0.016).
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Report a problemFND-0153146403
07HumanNon-randomized trialEfficacy outcome
In patients with endometriosis, post-nafarelin symptoms remained less severe than at admission at all assessed times (P less than or equal to 0.016).
In plain wordsIn patients with endometriosis, symptoms after nafarelin remained less severe than at admission at all assessed times.
Peptide
Nafarelin
Outcome
DecreasePost-treatment symptom severity versus admission
Study
n = 171
Comparator
Admission
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
200 micrograms twice daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After treatment, symptoms returned in each group, but severity was less than at admission at all time points (P less than or equal to 0.016).
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized, double-blind, double-dummy.
Summary · context
In total, 307 patients with laparoscopically diagnosed endometriosis received nafarelin (n = 206) or danazol (n = 101); 263 (171 nafarelin, 92 danazol) were analyzed for efficacy.
Summary · context
Intranasal nafarelin 200 micrograms two times a day or oral danazol 200 mg three times a day were administered for 6 months.
Report a problemFND-0153146404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.